Melanie Szweras
Partner | Bereskin & Parr LLP
Ronald E. Cahill
Partner, IP and Litigation Depts. Chair, Life Sciences Practice Group | Barnes & Thornburg LLP
Jason A. Lief
Partner | Windels Marx Lane & Mittendorf, LLPBiotech and Pharmaceutical Patent Law: Cutting-Edge Issues to Watch For | On-Demand Webinar
Webinar Date: Friday, September 16, 2022, from 12:00 pm to 1:30 pm (ET)
Several court cases continue to shape the biotech and pharmaceutical patent litigation in the United States and Canada.
In the United States, Amgen Inc. v. Sanofi-Aventis (2021) has revived the discussion on the enablement of genus claims in biotechnology inventions. Moreover, the multiple filings for abbreviated new drug applications (ANDA) also raise concerns, particularly in cases that may provoke multidistrict litigation. These and other developments further expand the patent litigation landscape, introducing new regulations that practitioners must be aware of to avoid legal pitfalls.
In Canada, summary trials are increasingly affecting the way litigation is proceeding. Issues concerning cases that impact the scope of the Notice of Allegation, certificates of supplementary protection, and the Patent Medicines Price Review Board, as well as those relating to claim construction, obviousness, and patentable subject matter, must be considered.
Join a panel of key thought leaders and distinguished professionals organized by The Knowledge Group as they provide a comprehensive discussion of the recent litigation trends in the biotech and pharmaceutical industry. Speakers, among other things, will also offer practical tips and strategies in this ever-changing regulatory landscape.
Some of the major topics that will be covered in this course are:
- Recent Litigation Trends and Developments in the Biotech and Pharmaceutical Industry
- Enablement of Genus Claims for Biotechnology Inventions
- Multiple Filing of Abbreviated New Drug Applications (ANDA): Implications
- Recent and Notable Court Cases
- What Lies Ahead
Agenda:
SEGMENT 1:
Melanie Szweras, Partner, Bereskin & Parr LLP
- Pleadings: Scope of the Notice of Allegation
- Summary trials – becoming increasingly popular
- Claim construction, obviousness, overbreadth, patentable subject matter
- Certificates of Supplementary Protection
- PMPRB
SEGMENT 2:
Ronald E. Cahill, Partner, IP and Litigation Depts. Chair, Life Sciences Practice Group, Barnes & Thornburg LLP
- The latest on inducing infringement through labels and other public statements;
- Emerging IPR strategies: When to expect IPRs as a supplement or replacement for Federal Court litigation; and
- New PTO guidance and recent inequitable conduct cases involving submissions to other government entities, including the FDA.
SEGMENT 3:
Jason A. Lief, Partner, Windels Marx Lane & Mittendorf, LLP
- “The Rise of the Section 112 Defense” in U.S. Pharmaceutical Patent Cases – Survey of case-law from pre-Ariad to Ariad to Juno Therapeutics
- “Sudden Death in U.S. Patent Cases” – Early Dispositive Motions on
- Section 101
- Summary Judgment of Invalidity
- Dedication-Disclosure Doctrine
Who Should Attend:
- Patent Attorneys and Consultants
- Biotech/Pharma Industry Lawyers
- Patent Managers
- Intellectual Property Attorneys and Consultants
- General Counsel
Register for this course by clicking the “Take this Course” at the top of the page.
CLE Credit:
Course Level:
Intermediate
Advance Preparation:
Print and review course materials
Method of Presentation:
On-demand Webcast (CLE)
Prerequisite:
General knowledge of Biotech and Pharmaceutical Patent Law
Course Code:
149871
NY Category of CLE Credit:
Area of Professional Practice
Total Credits:
1.5 CLE
How to Claim CLE Credits Per State:
CLE State Requirements:
https://knowlearninghub.com/cle-rules-map/
CPE State Requirements: